Table 3. Comparisons of the Prevalence of Prognostic Factors between Preoperative PLR Quartile Groups.
| Variable | Group 1 | Group 2 | Group 3 | Group 4 | P value |
|---|---|---|---|---|---|
| No. in quartile | 266 | 266 | 266 | 268 | |
| PLR, range | 13.32-103.85 | 104.01-125.96 | 126.0-155.97 | 156.25-407.81 | |
| Age, yr | 52.93±10.62 | 49.56±11.26a | 49.72±11.36a | 48.62±11.25a | <0.001 |
| BMI, kg/m2 | 23.87±3.26 | 23.51±3.23 | 23.85±13.27 | 23.16±2.91 | 0.631 |
| Tumor size, cm | 0.87±0.60 | 0.86±0.60 | 0.88±0.59 | 0.84±0.55 | 0.914 |
| TSH, mIU/L | 1.37 (0.90-2.33) | 1.32 (0.78-2.10) | 1.42 (0.93-2.24) | 1.32 (0.87-2.18) | 0.212 |
| T stage 3/4, % | 33 (12.4) | 24 (9.0) | 33 (12.4) | 32 (11.9) | 0.554 |
| LNM, % | 159 (59.8) | 154 (57.9) | 166 (62.4) | 155 (57.8) | 0.675 |
| Lateral LNM, % | 8 (3.0) | 18 (6.8) | 25 (9.4) | 14 (5.2) | 0.018 |
| Multifocality, % | 90 (33.8) | 70 (26.3) | 82 (30.8) | 78 (29.1) | 0.287 |
| ETE, % | 96 (36.1) | 100 (37.6) | 120 (45.1) | 96 (35.8) | 0.092 |
| LVI, % | 46/177 (26.0) | 43/168 (25.6) | 52/182 (29.1) | 49/188 (26.1) | 0.865 |
| BRAF V600E mutation, % | 155/254 (61.0) | 156/249 (62.7) | 152/248 (61.3) | 157/252 (62.3) | 0.978 |
Values are expressed as mean±SD, median (interquartile range), or number (%). Statistical significance was tested by one-way analysis of variance, or the chi-square test.
PLR, platelet-to-lymphocyte count ratio; BMI, body mass index; TSH, thyroid-stimulating hormone; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.
aThe differences were significant only between quartile group 1 and quartile group 2, 3, and 4 in post hoc analysis.